Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT05070130
Other study ID # PRIME CLASS
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date September 19, 2022
Est. completion date April 4, 2023

Study information

Verified date April 2023
Source Opsens, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In this study it is aimed to determine the diagnostic value of physiological measurements in the presence of aortic stenosis, and whether these are more accurate than angiographic assessment. Post-TAVR FFR will be taken as the reference for predicting ischemic lesions, and angiography and physiology - FFR and diastolic pressure ratio (dPR) - will be performed immediately before and after TAVR, in an all-comer multicentric observational study.


Description:

This is a post-marketing, prospective, observational, single arm, multi-center, single country study in Subjects who have severe symptomatic aortic stenosis with a formal indication for TAVR, and one or more intermediate coronary lesions in a relevant coronary artery (>2mm). This study aims to assess if OpSens non-hyperemic dPR (based on a proprietary algorithm) and/or OpSens FFR are suitable methods for the physiological assessment and prediction of ischemic coronary lesions in Subjects with aortic stenosis who are considered for TAVR. This will be done by comparing pre-TAVR measurements of angiography, dPR and FFR and placing them against the post-TAVR FFR, which is considered as the gold standard. Also the post TAVR dPR will be compared with post-TAVR FFR. A maximum of 137 subjects will be enrolled in 5 to 10 sites in Spain to obtain the required minimum of 137 lesions (see section 11.2 Sample Size Determination) The main hypothesis is that the specificity to predict ischemic lesions in TAVR candidates based on a pre-TAVR dPR ≤ 0.89 is superior compared to the specificity based on angiography alone (both QCA and visual assessment of the stenosis >50%), taking the post-TAVR FFR value of ≤ 0.80 as a reference for positive lesions. The pressure guidewire used to measure dPR and FFR during diagnostic angiography is the commercially available (CE-marketed) OptoWire family of pressure guidewires from OpSens Inc.


Recruitment information / eligibility

Status Terminated
Enrollment 32
Est. completion date April 4, 2023
Est. primary completion date March 15, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Subject is at least 18 years old - Subject has a degenerative aortic stenosis with mean valvular gradient =40 mmHg - Subject has a formal heart-team indication for TAVR - Subject has one or more stable coronary stenosis lesions 30-90% by visual estimation, in a vessel over 2 mm in diameter, and which is amenable for pressure-wire analysis - Subject agrees to participate in the study and is able to sign the informed consent form Exclusion Criteria: - Subject is unable to provide informed consent - Subject has asthma or acute bronchospasm - Subject has unstable angina or myocardial infarction - Subject meets any contraindication in the applicable OptoWire IFU - Subject is pregnant

Study Design


Intervention

Device:
dPR and FFR
OpSens non-hyperemic dPR and/or OpSens FFR

Locations

Country Name City State
Spain Hospital Universitari Germans Trias i Pujol Badalona
Spain Hospital Gregorio Maranon Madrid
Spain Hospital Virgen de la Victoria Malaga
Spain Hospital Clinico de Santiago Santiago De Compostela
Spain Hospital Clinico Universitario de Valladolid Valladolid

Sponsors (1)

Lead Sponsor Collaborator
Opsens, Inc.

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Other Success rate The success rate of the dPR & FFR procedure, defined as the percentage of cases in which dPR and FFR could be measured, and no procedural complications occurred Immediately upon completion of the TAVR procedure
Other Freedom from adenosine administration The percentage of Subjects who can be spared the administration of adenosine by a hybrid dPR-FFR strategy, while maintaining an overall diagnostic accuracy = 90% Immediately upon completion of the TAVR procedure
Other Percentage of concordance and mean difference between pre- and post-TAVR dPR Percentage of concordance and mean difference between pre- and post-TAVR dPR Immediately upon completion of the TAVR procedure
Other Percentage of concordance and mean difference between pre- and post-TAVR FFR Percentage of concordance and mean difference between pre- and post-TAVR FFR Immediately upon completion of the TAVR procedure
Primary Difference between preTAVR dPR specificity and angiography specificity for ischemia The difference between PreTAVR dPR specificity (%) - angiography specificity (%), taking post-TAVR FFR as the reference measure. Immediately upon completion of the TAVR procedure
Primary Diagnostic accuracy Establish sufficiently precise estimates (+/- 6.5% around estimate) for the diagnostic accuracy of pre-TAVR dPR expressed in terms of sensitivity and specificity, taking as the reference for ischemia the post-TAVR FFR Immediately upon completion of the TAVR procedure
Secondary Difference in accuracy between dPR and angiography The difference between the percentage of lesions correctly classified by preTAVR dPR and the percentage of lesions correctly classified by angiography, always taking postTAVR FFR as the reference measure. Immediately upon completion of the TAVR procedure
Secondary Difference in sensitivity between dPR and angiography The difference between the sensitivity of preTAVR dPR and the sensitivity of angiography, where:
preTAVR sensitivity= preTAVR True positive/ (preTAVR true positive+ preTAVR false negative) * 100
angiography sensitivity= angiography True positive/ (angiography true positive+ angiography false negative) * 100,
taking post-TAVR FFR as the reference measure.
Immediately upon completion of the TAVR procedure
Secondary Predicting post-TAVR FFR by pre-TAVR FFR Overall diagnostic accuracy of preTAVR FFR, defined as the percentage of lesions correctly classified by pre-TAVR FFR, taking postTAVR FFR as the reference measure. Immediately upon completion of the TAVR procedure
Secondary Difference in accuracy between preTAVR dPR and preTAVR FFR The difference in the overall diagnostic accuracy of pre-TAVR dPR and pre-TAVR FFR to predict a post-TAVR FFR = 0.80 Immediately upon completion of the TAVR procedure
Secondary Predicting post-TAVR FFR by pre-TAVR hybrid dPR-FFR Overall diagnostic accuracyof a pre-TAVR hybrid dPR-FFR based approach to predict a post-TAVR FFR = 0.80 Immediately upon completion of the TAVR procedure
See also
  Status Clinical Trial Phase
Recruiting NCT04310046 - Optimal Timing of Transcatheter Aortic Valve Implantation and Percutaneous Coronary Intervention - The TAVI PCI Trial N/A
Recruiting NCT06008080 - Post-Market Clinical Follow Up Study With Navitor Valve
Recruiting NCT06055751 - Long Term Evaluation of Cardiac Arrhythmias After Transcatheter Aortic Valve Implantation -The LOCATE Registry
Active, not recruiting NCT04815785 - Safety and Efficacy of TaurusOne® Transcatheter Aortic Valve System in Patients With Severe Calcific Aortic Stenosis N/A
Terminated NCT02202434 - Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement N/A
Recruiting NCT03029026 - The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis.
Active, not recruiting NCT02903420 - A Clinical Trial of Transcatheter Aortic Valves in Dialysis Patients (Japan) N/A
Completed NCT02629328 - CardioCel Tri-leaflet Repair Study N/A
Completed NCT02306226 - Symetis ACURATE Neo™ Valve Implantation SAVI TF Registry
Withdrawn NCT01648309 - Neuropsychological Testing in Patients Undergoing Transvascular Aortic Valve Implantation N/A
Completed NCT01676727 - ADVANCE Direct Aortic Study
Completed NCT01422044 - Risk Prediction in Aortic Stenosis N/A
Withdrawn NCT00774657 - Ventricular Remodeling In Patients With Aortic Stenosis Assessed Echocardiography N/A
Terminated NCT00535899 - Speckle Tracking Imaging in Patients With Low Ejection Fraction Aortic Stenosis (SPArKLE-AS) N/A
Completed NCT03314857 - China XT: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population N/A
Completed NCT04157920 - Impact of Predilatation Between Self-expanding Valves N/A
Enrolling by invitation NCT06212050 - Feasibility, Safety, and Effectiveness of the ACURATE neo2 Transcatheter Heart Valve for Severe Bicuspid Aortic Stenosis
Recruiting NCT05893082 - Multicenter Feasibility Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR N/A
Completed NCT03250806 - Early Detection of Aortic Stenosis in the Community During Flu Vaccination
Enrolling by invitation NCT04031274 - Transcatheter Treatment for Combined Aortic and Mitral Valve Disease. The Aortic+Mitral TRAnsCatheter (AMTRAC) Valve Registry